Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
AbbVie,Risankizumab,Moderate to severe plaque psoriasis - first line biologic,Risankizumab,Community and Hospital,Dermatologicals
